From: Quality of life and emotional distress in advanced prostate cancer survivors undergoing chemotherapy
Authors | Chemotherapeutic agent | QOL measure | Direction of effect |
---|---|---|---|
Tannock et al. (1996) | Mitoxantrone | EORTC QLQ-30; Pain rating | Improved pain, mood & physical activity |
Beer et al., (2001) | Docetaxel | Present Pain Intensity scale | Improved pain |
Sinibaldi et al. (1999) | Docetaxel | Brief Pain Inventory | Improved pain |
Copur et al. (2001) | Docetaxel | Numeric rating scale | Improved pain |
Gravis et al. (2003) | Docetaxel | EORTC QLQ-30; Pain VAS | Improved role, social functioning, overall QOL, pain, fatigue, constipation |
Small et al. (2000) | Suramin | Brief Pain Inventory | Improved pain |
Fuse et al. (1996) | Cisplatin/carboplatin | Rating scale | Improved pain |
Kreis et al. (1999). | Docetaxel | Physician-graded events | Presence of fatigue dose-limiting factor |
Hamilton et al. (2003) | Vinblastine | Physician-graded events | Presence of fatigue dose-limiting factor |
van Andel et al. (2003) | Epirubicin | QLQ-30 | Reduced fatigue, transient improvement in emotional, social and cognitive functioning |
Kornblith et al. (2001) | Docetaxel | FACT-P, Mental Health Inventory-17 | Transient improvements in emotional well-being, improved overall QOL |